REGENERON PHARMACEUTICALS, INC. Total Liabilities
REGENERON PHARMACEUTICALS, INC. (REGN) had Total Liabilities of $10.02 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-07-30
- 2026-06-30: Liabilities $10.02B.
- 2026-03-31: Liabilities $9.45B.
- 2025-12-31: Liabilities $9.30B.
- 2025-09-30: Liabilities $9.21B.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $10.02B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $9.45B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $9.30B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $9.21B 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $8.28B 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $8.16B 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $8.41B 10-K · filed 2026-02-04 | |
| 2024-09-30 | $8.12B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $7.88B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $7.38B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $7.11B 10-K · filed 2025-02-05 | |
| 2023-09-30 | $7.26B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $6.64B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $6.56B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $6.55B 10-K · filed 2024-02-05 | |
| 2022-09-30 | $6.24B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $6.52B 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $6.43B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $6.67B 10-K · filed 2023-02-06 | |
| 2021-09-30 | $6.41B 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $6.36B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $5.80B 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $6.14B 10-K · filed 2022-02-07 | |
| 2020-09-30 | $5.96B 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $5.37B 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $3.62B 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $3.72B 10-K · filed 2021-02-08 | |
| 2019-09-30 | $3.43B 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $3.42B 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $3.41B 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $2.98B 10-K · filed 2020-02-07 | |
| 2018-09-30 | $2.94B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $2.77B 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $2.81B 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $2.62B 10-K · filed 2019-02-07 | $2.62B 10-K · filed 2018-02-08 |
| 2017-09-30 | $2.65B 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $2.59B 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $2.95B 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $2.52B 10-K · filed 2018-02-08 | |
| 2016-09-30 | $2.34B 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $2.13B 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $2.14B 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $1.95B 10-K · filed 2017-02-09 | |
| 2015-09-30 | $1.89B 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $1.19B 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $1.23B 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $1.29B 10-K · filed 2016-02-11 | $1.33B 10-K · filed 2015-02-12 |
| 2014-09-30 | $1.19B 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $1.09B 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $1.05B 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $998.94M 10-K · filed 2015-02-12 | |
| 2013-09-30 | $950.24M 10-Q · filed 2013-11-05 | |
| 2013-06-30 | $884.92M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $869.65M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $835.11M 10-K · filed 2014-02-13 | |
| 2012-09-30 | $854.59M 10-Q · filed 2012-10-24 | |
| 2012-06-30 | $862.84M 10-Q · filed 2012-07-25 | |
| 2012-03-31 | $846.13M 10-Q · filed 2012-04-26 | |
| 2011-12-31 | $837.85M 10-K · filed 2013-02-15 | |
| 2011-09-30 | $554.78M 10-Q · filed 2011-10-27 | |
| 2011-06-30 | $568.83M 10-Q · filed 2011-07-28 | |
| 2011-03-31 | $556.20M 10-Q · filed 2011-05-03 | |
| 2010-12-31 | $561.62M 10-K · filed 2012-02-21 | |
| 2010-09-30 | $594.37M 10-Q · filed 2010-10-28 | |
| 2010-06-30 | $419.43M 10-Q · filed 2010-07-28 | |
| 2009-12-31 | $344.44M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |